中国癌症防治杂志
中國癌癥防治雜誌
중국암증방치잡지
CHINESE JOURNAL OF ONCOLOGY PREVENTION AND TREATMENT
2014年
1期
25-29
,共5页
阳诺%马辉%冼磊%陈铭伍
暘諾%馬輝%冼磊%陳銘伍
양낙%마휘%승뢰%진명오
肺肿瘤%非小细胞肺癌%ERCC1%BAG-1%BRCA1%化疗%预后
肺腫瘤%非小細胞肺癌%ERCC1%BAG-1%BRCA1%化療%預後
폐종류%비소세포폐암%ERCC1%BAG-1%BRCA1%화료%예후
Lung neoplasm%Non-small cell lung cancer%ERCC1%BAG-1%BRCA1%Chemotherapy%Prognosis
目的：探讨ERCC1、BAG-1和BRCA1基因mRNA在接受以铂类为基础辅助化疗的非小细胞肺癌（non-small cell lung cancer，NSCLC）患者中的表达情况及其与预后的关系。方法85例NSCLC患者中74例给予以铂类为基础的术后辅助化疗，采集全组患者的肿瘤组织和其中34例患者的癌旁组织，应用半定量RT-PCR法，检测其ERCC1、BAG-1和BRCA1基因mRNA的表达情况，回顾性分析患者的临床病理资料，探讨3个基因的表达与患者总生存期（OS）之间的关系。结果①ERCC1、BAG-1阴性表达的患者OS显著长于阳性表达的患者（P均=0.001）。ERCC1、BAG-1阴性表达的患者接受铂类化疗的疗效显著优于阳性表达的患者（P=0.002、P=0.001）。于BRCA1阴性表达的患者OS长于阳性表达的患者，但差异无统计学意义（P=0.057）。③多因素分析显示ERCC1、BAG-1可作为NSCLC患者接受铂类化疗的预后指标（P=0.027、P=0.022）。结论检测ERCC1和BAG-1的表达可作为指导NSCLC患者术后接受铂类化疗及预后评估的指标。
目的：探討ERCC1、BAG-1和BRCA1基因mRNA在接受以鉑類為基礎輔助化療的非小細胞肺癌（non-small cell lung cancer，NSCLC）患者中的錶達情況及其與預後的關繫。方法85例NSCLC患者中74例給予以鉑類為基礎的術後輔助化療，採集全組患者的腫瘤組織和其中34例患者的癌徬組織，應用半定量RT-PCR法，檢測其ERCC1、BAG-1和BRCA1基因mRNA的錶達情況，迴顧性分析患者的臨床病理資料，探討3箇基因的錶達與患者總生存期（OS）之間的關繫。結果①ERCC1、BAG-1陰性錶達的患者OS顯著長于暘性錶達的患者（P均=0.001）。ERCC1、BAG-1陰性錶達的患者接受鉑類化療的療效顯著優于暘性錶達的患者（P=0.002、P=0.001）。于BRCA1陰性錶達的患者OS長于暘性錶達的患者，但差異無統計學意義（P=0.057）。③多因素分析顯示ERCC1、BAG-1可作為NSCLC患者接受鉑類化療的預後指標（P=0.027、P=0.022）。結論檢測ERCC1和BAG-1的錶達可作為指導NSCLC患者術後接受鉑類化療及預後評估的指標。
목적：탐토ERCC1、BAG-1화BRCA1기인mRNA재접수이박류위기출보조화료적비소세포폐암（non-small cell lung cancer，NSCLC）환자중적표체정황급기여예후적관계。방법85례NSCLC환자중74례급여이박류위기출적술후보조화료，채집전조환자적종류조직화기중34례환자적암방조직，응용반정량RT-PCR법，검측기ERCC1、BAG-1화BRCA1기인mRNA적표체정황，회고성분석환자적림상병리자료，탐토3개기인적표체여환자총생존기（OS）지간적관계。결과①ERCC1、BAG-1음성표체적환자OS현저장우양성표체적환자（P균=0.001）。ERCC1、BAG-1음성표체적환자접수박류화료적료효현저우우양성표체적환자（P=0.002、P=0.001）。우BRCA1음성표체적환자OS장우양성표체적환자，단차이무통계학의의（P=0.057）。③다인소분석현시ERCC1、BAG-1가작위NSCLC환자접수박류화료적예후지표（P=0.027、P=0.022）。결론검측ERCC1화BAG-1적표체가작위지도NSCLC환자술후접수박류화료급예후평고적지표。
Objective To investigate the expression and prognostic usefulness of ERCC1,BAG-1 and BRCA1 in patients with non-small cell lung cancer(NSCLC)treated with platinum-based adjuvant chemotherapy. Methods RT-PCR was used to investigate the mRNA expression of ERCC1,BAG-1 and BRCA1 in 85 samples of NSCLC tissues and 34 tumor-adjacent tissues.Relationships of the expression of these three genes with overall survival (OS)were analyzed. Results ①OS was significantly longer in patients negative for ERCC1 or BAG-1 mRNA expression than in those positive for expression of either gene (P=0.001).Platinum-based chemotherapy was more effective for patients negative for ERCC1 or BAG-1 than for the corresponding positive patients (P=0.001 and P=0.002), respectively.②OS may be longer in patients negative for BRCA1 mRNA expression than in BRCA1-positive patients(P=0.052).③Multivariate analysis suggests that ERCC1 and BAG-1 may be prognostic indicators for patients receiving platinum-based adjuvant chemotherapy (P=0.027 and P=0.022). Conclusion Expression of ERCC1 and BAG-1 mRNA may be useful in the prognosis of NSCLC treated with platinum.
